• TScan Therapeutics held its annual shareholder meeting on May 20, 2026.
• Shareholders backed an amendment to the certificate of incorporation to raise authorized shares of voting common stock to 600,000,000 from 300,000,000.
• The amendment was executed through the filing of a certificate of amendment on May 20, 2026, which became effective upon filing.
• Shareholders ratified Deloitte & Touche as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders also cleared a proposal to adjourn the meeting, though it was not needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-236862), on May 22, 2026, and is solely responsible for the information contained therein.